bioAffinity Technologies Inc. reported total revenue of $1.5 million for the third quarter ended September 30, 2025, down from $2.4 million in the same period of 2024, primarily due to the discontinuation of unprofitable pathology services. CyPath Lung testing revenue for the quarter increased approximately 122% year-over-year, reflecting higher physician adoption and test volume. Net loss for the quarter was $5.1 million, or $4.74 per share, compared to a net loss of $2.0 million, or $4.84 per share, in the third quarter of 2024, mainly due to the change in fair value of warrants issued. Operating expenses fell 16% year-over-year to $3.7 million, while depreciation and amortization expense declined 25% to $113,000. Cash and cash equivalents rose to $7.7 million as of September 30, 2025, following $10.4 million in gross proceeds from equity transactions. Sales of CyPath Lung reached a record high in the third quarter, increasing 92% over the previous quarter, with notable growth in adoption by VA hospitals and in the mid-Atlantic region.